Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study

Despite the extensive use of the combination of cytotoxic chemotherapy and programmed cell death protein 1/programmed death-ligand 1 checkpoint inhibitors for cancer treatment, the incidence and characteristics of pneumonitis caused by this combination therapy have not been examined in clinical sett...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2021-06, Vol.150, p.63-72
Hauptverfasser:	Fujimoto, Daichi, Miura, Satoru, Yoshimura, Kenichi, Wakuda, Kazushige, Oya, Yuko, Yokoyama, Toshihide, Yokoi, Takashi, Asao, Tetsuhiko, Tamiya, Motohiro, Nakamura, Atsushi, Yoshioka, Hiroshige, Haratani, Koji, Teraoka, Shunsuke, Tokito, Takaaki, Murakami, Shuji, Tamiya, Akihiro, Itoh, Shoichi, Yokouchi, Hiroshi, Watanabe, Satoshi, Yamaguchi, Ou, Tomii, Keisuke, Yamamoto, Nobuyuki
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Apoptosis Cancer therapies Cell death Chemotherapy Cohort analysis Cytotoxicity Immune checkpoint Immune checkpoint inhibitor Immunotherapy Lung cancer Non-small cell lung cancer Non-small cell lung carcinoma Patients PD-1 PD-L1 Pembrolizumab Platinum Pneumonia Pneumonitis Small cell lung carcinoma Survival Survival analysis World population
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!